Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger than expected Q3 results earlier this month, with revenues growing by ~27% year-over-year to $192 million, beating estimates by almost $13 million, driven by strong sales of the Omnipod system. The company has had some favorable news on the regulatory front, gaining FDA approval for the use of Novo Nordisk’s Fiasp -a fast-acting mealtime insulin – with the Omnipod insulin management platform. Separately, in September, the FDA cleared the company’s ACE pump. This could help the company drive revenue growth.
We ‘step back’ from these recent swings to review Insulet’s performance over the last few years, as a context for what might come next. Our Interactive dashboard, Why Has Insulet Stock Rallied Over The Last Month?, reviews the near term reasons and the big picture.
The context for the last few years:
A closer look At Insulet’s Total Revenues over the last few years and the outlook
Total Revenues for Insulet significantly increased from $464 Mil in 2017 to $564 Mil in 2018; an increase of 21.6%.
This compares with Total Revenues growth of:
- 14.1% in 2015
- 39.1% in 2016
- 26.4% in 2017
We expect Total Revenues growth to be 29.5% in 2019.
A closer look At Insulet’s Total Expenses over the last few years and the outlook
Total Expense for Insulet increased from $490 Mil in 2017 to $559 Mil in 2018; an increase of 13.9%.
This compares with Total Expense growth of:
- 16.5% in 2015
- 21.1% in 2016
- 24.5% in 2017
We expect Total Expense growth to stand at 28% in 2019.
How does Insulet’s Revenue Growth compare with Abbott and Tandem Diabetes Care?
For more information on how Insulet’s revenue growth compares with rivals, view our interactive dashboard analysis.
How has Insulet’s EBT trended?
EBT for Insulet increased dramatically by -120% from -$26.6 Mil in 2017 to $5.23 Mil in 2018.
We expect EBT to increase to $16.6 million in 2019.
How has Insulet’s Net Income and EPS trended?
For more information on Insulet’s Net Income and EPS, view our interactive dashboard analysis.
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams| Product, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own